



IFW

PATENT
Customer No. 22,852
Attorney Docket No. 10142.0003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Evy LUNDGREN-AKERLUND) Group Art Unit: 1644
)
Application No.: 10/517,421) Examiner: Maher M. Haddad
)
Filed: June 13, 2005) Confirmation No.: 5691
)
For: METHODS AND USES OF THE)
INTEGRIN ALPHA 10 CHAIN,)
FOR PREVENTING)
PROGRESSION OF)
ATHEROSCLEROSIS PLAQUE)
FORMATION)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(c)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicant bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed after the events recited in Section 1.97(b), but, to the undersigned's knowledge, before the mailing date of either a Final action, Quayle action, or a Notice of Allowance. Under the provisions of 37 C.F.R. § 1.97(c), this Information Disclosure Statement is accompanied by a fee of \$180.00 as specified by Section 1.17(p).

Copies of the listed foreign and non-patent literature documents are attached. Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

12/14/2006 12:00:00 PM 10142.0003 10517421

01 FD:1636

100.00 07

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicant determines that the cited documents do not constitute "prior art" under United States law, Applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,


FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: December 13, 2006

By: 

John C. Stolpa
Reg. No. 57,632

Enclosures



IDS Form PTO/SB/08: Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/517,421
Filing Date	June 13, 2005
First Named Inventor	Evy LUNDGREN-AKERLUND
Art Unit	1644
Examiner Name	Maier M. Haddad
Attorney Docket Number	10142.0003

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initials	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-7,029,858	04-18-2006	Lundgren-Akerlund	
		US-2006/0127398	6-15-2006	Lundgren-Akerlund	
		US-2006/0178503	08-10-2006	Lundgren-Akerlund	

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		WO 90/11676	10-18-1990	Centocor, Inc.		
		WO 97/14432	04-24-1997	Cor Therapeutics, Inc.		
		WO 99/51639	10-14-1999	Active Biotech AB		
		WO 03/068262	08-21-2003	Biogen, Inc.		
		WO 2004/089990	10-24-2004	Cartela AB		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
		CAMPER et al., "Isolation, cloning, and sequence analysis of the integrin subunit alpha10, a beta1-associated collagen binding integrin expressed on chondrocytes," J Biol Chem., Vol. 273, pages 20383-20389, August 7, 1998	
		CAMPER et al., "Distribution of the collagen-binding integrin alpha10beta1 during mouse development," Cell Tissue Res., Vol. 306, pages 107-116, October, 2001.	
		CHIA, "The role of adhesion molecules in atherosclerosis," Crit Rev Clin Lab Sci., Vol. 35, pages 573-602, 1998.	
		CORTI et al., "New understanding of atherosclerosis (clinically and experimentally) with evolving MRI technology in vivo," Ann NY Acad Sci., Vol. 947, pages 181-95, December, 2001.	
		DE MELKER et al., "The two phenylalanines in the GFFKR motif of the integrin alpha6A subunit are essential for heterodimerization," Biochem J., Vol. 328, pages 529-537, December, 1997.	
		DIMAYUGA et al., "Reconstituted HDL containing human apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following periaortic cuff-induced carotid injury in apoE null mice," Biochem Biophys Res Commun., Vol. 264, pages 465-468, October 22, 1999.	
		FAYAD et al., "Clinical imaging of the high-risk or vulnerable atherosclerotic plaque," Circ Res., Vol. 89, pages 305-316, August 17, 2001.	
		FLACKE et al., "Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques," Circulation, Vol. 104, pages 1280-1285, September 11, 2001.	
		FUSTER, "Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology," Circulation, Vol. 90, pages 2126-2146, October, 1994.	
		HYNES, "Integrins: versatility, modulation, and signaling in cell adhesion," Cell, Vol. 69, pages 11-25, April 3, 1992.	
		KOZARSKY, "Gene therapy for cardiovascular disease," Curr Opin Pharmacol., Vol. 1, pages 197-201, April, 2001.	
		NAGHAVI et al., "New developments in the detection of vulnerable plaque," Curr Atheroscler Rep., Vol. 3, pages 125-135, March, 2001.	
		RAINES, "The extracellular matrix can regulate vascular cell migration, proliferation, and survival: relationships to vascular disease," Int J Exp Pathol., Vol. 81, pages 173-182, June 2000.	

IDS Form PTO/SB/08: Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/517,421	
			Filing Date	June 13, 2005	
			First Named Inventor	Evy LUNDGREN-AKERLUND	
			Art Unit	1644	
			Examiner Name	Maher M. Haddad	
			Attorney Docket Number	10142.0003	
Sheet	2	of	2		

NON PATENT LITERATURE DOCUMENTS			
		SKINNER et al., "Dynamic expression of alpha 1 beta 1 and alpha 2 beta 1 integrin receptors by human vascular smooth muscle cells. Alpha 2 beta 1 integrin is required for chemotaxis across type I collagen-coated membranes," Am J Pathol., Vol. 145, pages 1070-1081, November, 1994.	
		STARY et al., "A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association," Circulation, Vol. 92, pages 1355-1374, September 1, 1995.	
		TALTS et al., "Integrin gene targeting," Methods Mol Biol., Vol. 129, pages 153-187, 1999.	
		TANGIRALA et al., "Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice," Circulation, Vol. 100, pages 1816-1822, October 26, 1999.	
		THYBERG et al., "Regulation of differentiated properties and proliferation of arterial smooth muscle cells," Arteriosclerosis, Vol. 10, pages 966-990, November, 1990.	
		TSIMIKAS et al., "In vivo uptake of radiolabeled MDA2, an oxidation-specific monoclonal antibody, provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression," Arterioscler Thromb Vasc Biol., Vol. 20, pages 689-697, March, 2000.	
		YU et al., "High-resolution MRI characterization of human thrombus using a novel fibrin-targeted paramagnetic nanoparticle contrast agent," Magn Reson Med., Vol. 44, pages 867-872, December, 2000.	
		ZHU et al., "Both apolipoprotein E and immune deficiency exacerbate neointimal hyperplasia after vascular injury in mice," Arterioscler Thromb Vasc Biol., Vol. 22, pages 450-455, March 1, 2002.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.